The Bax/Bcl-2 Ratio Determines the Susceptibility of Human Melanoma Cells to CD95/Fas-Mediated Apoptosis  by Raisova, Monika et al.
The Bax/Bcl-2 Ratio Determines the Susceptibility of Human
Melanoma Cells to CD95/Fas-Mediated Apoptosis
Monika Raisova, Amir M. Hossini, JuÈrgen Eberle, Christian Riebeling, Thomas Wieder,* Isrid Sturm,*
Peter T. Daniel,* Constantin E. Orfanos, and Christoph C. Geilen
Department of Dermatology, University Medical Center Benjamin Franklin, Free University of Berlin; *Department of Hematology, Oncology and
Tumor Immunology, University Medical Center ChariteÂ, Campus Berlin-Buch, Humboldt University Berlin, Germany
Defective cytochrome c release and the resulting loss
of caspase-3 activation was recently shown to be
essential for the susceptibility of human melanoma
cells to CD95/Fas-induced apoptosis. Cytochrome c
release from mitochondria is regulated by the rela-
tive amounts of apoptosis-promoting and apoptosis-
inhibiting Bcl-2 proteins in the outer membrane of
these organelles. The assignment of Bax/Bcl-2 ratios
by quantitative Western blotting in 11 melanoma cell
populations revealed a relation to the susceptibility
to CD95-mediated apoptosis. We could show that a
low Bax/Bcl-2 ratio was characteristic for resistant
cells and a high Bax/Bcl-2 ratio was characteristic
for sensitive cells. Low Bax expression was not a
consequence of mutations in the p53 coding
sequence. The Bax/Bcl-2 ratio was also in clear cor-
relation with sensitivity to another cell death inducer,
N-acetylsphingosine. Furthermore, Bcl-2 overexpres-
sion abolished apoptosis triggered by both apoptotic
stimuli, con®rming the critical role of the Bax/Bcl-2
ratio as a rheostat that determines the susceptibility
to apoptosis in melanoma cells by regulating mito-
chondrial function. Interestingly, some chemothera-
peutics lead to the activation of death pathways by
CD95L upregulation, ceramide generation, direct
activation of upstream caspases, or upregulation of
proapoptotic genes. Taken together, these signals
enter the apoptotic pathway upstream of mitochon-
dria, resulting in activation of this central check-
point. We therefore assumed that apoptosis
de®ciency of malignant melanoma can be circum-
vented by drugs directly in¯uencing mitochondrial
functions. For this purpose we used betulinic acid, a
cytotoxic agent selective for melanoma, straightly
perturbing mitochondrial functions. In fact, betulinic
acid induced mitochondrial cytochrome c release and
DNA fragmentation in both CD95-resistant and
CD95-sensitive melanoma cell populations, inde-
pendent of the Bax/Bcl-2 ratio. Key words: Bax/Bcl-2
ratio/CD95/Fas/ceramide/melanoma. J Invest Dermatol
117:333±340, 2001
T
he CD95 system has been recognized as a major
pathway for the induction of apoptosis in cells and
tissues (Nagata and Golstein, 1995). CD95 is a
member of the tumor necrosis factor receptor
subfamily named death receptors. Human melanoma
cells have recently been shown to be heterogenously susceptible to
CD95-induced apoptosis. The elucidation of the mechanisms
underlying the resistance to CD95-mediated apoptosis in human
melanoma cells revealed that the cells resistant to CD95-induced
apoptosis failed to translocate cytochrome c into the cytosol and to
activate the downstream execution process (Raisova et al, 2000).
Developing resistance within the CD95-signaling pathway may
have two potential bene®ts for the tumor. First, it allows tumor
cells to avoid being killed by CD95L-positive cytotoxic T cells and
to escape from immune surveillance (Reed, 1999). Second, some
anticancer drugs have been shown to involve the CD95 pathway, at
least in T cells, so delivering apoptotic signals through an autocrine
mechanism (Friesen et al, 1999). Therefore, de®ciencies in the
CD95 apoptotic-signaling pathway might also be a clue to
de®nition of drug resistance in the tumor.
Cytochrome c release from mitochondria is a central event in
apoptosis. Upon exposure to a variety of proapoptotic stimuli
cytochrome c enters the cytosol and binds to the cytosolic Apaf-1
(apoptotic protease activating factor 1) and procaspase-9 (Li et al,
1997). This results in activation of caspase-9 and processing of the
main executioner caspase-3, thus reaching the ``point of no return''
(Enari et al, 1996). The release of cytochrome c is determined by
the relative amounts of apoptosis-promoting and apoptosis-inhibit-
ing Bcl-2 proteins in the outer membrane of the mitochondrion
(Adams and Cory, 1998). Inappropriate overexpression of
apoptosis-suppressing Bcl-2 protein has been shown to contribute
to tumorigenesis in various types of tumors, e.g., breast cancer
(Reed, 1996). The apoptosis-preventing effect of Bcl-2 is counter-
acted by the proapoptotic protein Bax. Imbalance of the Bax/Bcl-2
ratio that tilts the scales toward survival can render tumor cells more
resistant to a wide variety of cell death stimuli, including all
chemotherapeutic drugs, radiation, hypoxia, or growth factor
withdrawal (Reed, 1994). The broad resistance to cell death,
Manuscript received August 21, 2000; revised March 28, 2001; accepted
for publication March 30, 2001.
Reprint requests to: Prof. Christoph C. Geilen, Department of
Dermatology, University Medical Center Benjamin Franklin, Free
University of Berlin, Fabeckstr. 60±62, 14195-Berlin, Germany. Email:
CCGeilen@zedat.fu-berlin.de
Abbreviations: CD95L/FasL, CD95/Fas ligand; C2-ceramide, N-acetyl-
sphingosine; LDH, lactate dehydrogenase; SSCP, single stranded con-
formational polymorphism.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
333
occurring upon disturbed balance of the Bax/Bcl-2 ratio, can also
be relevant for cancer cell behavior, tumor cell invasion, cell
adhesion, or metastatic potential.
The p53 gene product is known to be an upstream regulator of
the bax gene (Miyashita and Reed, 1995). This tumor suppressor
binds to the bax gene promoter and directly transactivates the
transcription of this proapoptotic gene. The bax promoter can be
activated by wild-type but not mutant p53, which forms a link
between p53 expression, its mutational status, and alterations in Bax
expression. Surprisingly, the proapoptotic protein Bax has been
shown to be strongly expressed in most tissue samples of malignant
melanoma (Tang et al, 1998). An explanation for the Bax elevation
could be a frequently increased expression of wild-type p53 and a
low p53 mutation rate in human melanoma (10%) (Saenz-
Santamaria et al, 1995). The actions of Bax appear to be neutralized
when heterodimerized with Bcl-2 and some other members of the
Bcl-2 protein family, such as Bcl-xL and Mcl-1. Bcl-2 expression is
a common ®nding in melanocytic lesions regardless of their
biologic behavior, and the progression of malignant melanoma does
not depend on the overexpression of Bcl-2 (Selzer et al, 1998). As
shown in other tumors, the Bax/Bcl-2 ratio seems to be more
important in determining the sensitivity to apoptotic stimuli in
melanoma than the expression of each protein individually.
Ceramide is a proapoptotic molecule, recently shown to induce
cytochrome c release from isolated mitochondria (Ghafourifar et al,
1999). It is a signaling molecule involved in cellular responses to a
variety of apoptotic stimuli and its signi®cant role in the CD95
apoptotic pathway in human melanoma cells has recently been
demonstrated (Raisova et al, 2000). Ceramide generation in this
pathway has been molecularly ordered downstream of the adaptor
protein FADD (Fas-associated death domain) and upstream of
mitochondria and effector caspases (Okazaki et al, 1998). The
tumor-speci®c toxicity of some anticancer drugs was attributed to a
functional CD95 pathway. Betulinic acid is a new cytotoxic agent,
with a selective anticancer activity in tumors of neuroectodermal
origin, directly targeting mitochondria without triggering the
CD95/CD95L system (Pisha et al, 1995). Some forms of drug
resistance can be circumvented using betulinic acid most probably
by straight perturbation of mitochondrial functions (Fulda et al,
1998b, c).
In this study, we investigated the molecular mechanisms of
resistance to CD95- and ceramide-induced apoptosis in 11
melanoma cell populations. We could show by quantitative
Western blotting that the Bax/Bcl-2 protein expression ratios
determine the sensitivity to these apoptotic stimuli. The central role
of the Bax/Bcl-2 rheostat was con®rmed by Bcl-2 overexpression,
which blocked CD95/ceramide-induced apoptosis in sensitive
melanoma cells. Furthermore, betulinic acid, which directly targets
mitochondria and causes cytochrome c release, was able to
circumvent the apoptosis de®ciency of CD95/ceramide-resistant
melanoma cells.
MATERIALS AND METHODS
Materials The agonistic anti-CD95 monoclonal antibody CH-11
(Chemicon, Hofheim, Germany) was used at a ®nal concentration of
1 mg per ml. N-acetylsphingosine (C2-ceramide) was purchased from
Alexis (Gruenberg, Germany) and dissolved in ethanol to give a 20 mM
stock solution. pIRES1neo was purchased from Clontech (Palo Alto,
CA), and betulinic acid was provided from Sigma (Munich, Germany) as
pure substance and dissolved in dimethylsulfoxide to give a stock
solution of 4 mg per ml betulinic acid. Geneticin (G418) was from Life
Technologies (Karlsruhe, Germany).
Cell culture Two melanoma cell populations (M186, M221) were
obtained from patients with histologically con®rmed metastatic
melanoma by surgical intervention. Four out of nine established human
melanoma cell lines used in this study originated from primary tumors
[A-375 (Giard et al, 1973), Bro (Lockshin et al, 1985), JPC-298 (Aubert
et al, 1993); Mel-HO (Holzmann et al, 1988)] and ®ve cell lines
originated from metastases [Mel-2 A (Bruggen et al, 1981); MeWo (Bean
et al, 1975), SK-Mel-13, SK-MEL-23, SK-Mel-28 (Carey et al, 1976)].
All melanoma cell lines were grown in Dulbecco's modi®ed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
100 U per ml penicillin, and 100 mg per ml streptomycin.
Lipofection of melanoma cells The construction of pIRES/mbcl-2
has been reported previously and has been shown to be functional in
HaCaT keratinocytes (MuÈller-Wieprecht et al, 2000). Transfection of
melanoma cells was carried out using the lipofection reagent pFx-2 from
Invitrogen (Groningen, The Netherlands) following the supplier's
instructions. Brie¯y, the reagent was diluted 1:200 in OPTI-MEM
medium (Life Technologies) without FBS and 1.5 mg pIRES1neo/
mbcl-2 or pIRES1neo were added. The solution was added to
melanoma cells, grown to 30%±50% con¯uency in 3.5 cm dishes, and
incubated for 2 h at 37°C. Selection with 1.0 mg per ml geniticin started
48 h after transfection. After a selection and subcultivating period of
approximately 10 wk individual cell clones were isolated. Bcl-2
overexpression in these cell lines was con®rmed by Western blotting
(data not shown).
Western blot analysis Cells were lyzed in lysis buffer (1% Triton X-
100, 50 mM Tris, pH 7.4, 150 mM NaCl containing 1 mM leupeptin,
1 mM pepstatin, and 100 mM phenylmethylsulfonyl ¯uoride) followed by
dounce homogenization. The homogenate was centrifuged for 10 min at
400g to get rid of cell debris. Protein concentration was assayed using
bicinchoninic acid (Pierce, Weiskirchen, Germany). Then, 35 mg of
cytosolic protein were separated on a 15% sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) and blotted to nitrocellulose membrane
as described previously (Wieprecht et al, 1996). Membranes were
blocked for 1 h with 3% nonfat dry milk in phosphate-buffered saline
(PBS) containing 0.25% Tween-20 and then incubated with mouse
monoclonal anti-Bcl-2 antibodies (100/D5, Novocastra, Dossenheim,
Germany) at a 1:100 dilution, with mouse monoclonal anti-Bcl-2
antibodies (C-2, Santa Cruz, Heidelberg, Germany) at a 1:1000 dilution,
with mouse monoclonal anti-Bax antibody (YTH-2D2, Trevigen,
Gaithersburg) at a 1:10,000 dilution, or with rabbit polyclonal
anticaspase-9 antibodies (Pharmingen, Hamburg, Germany) at a 1:1000
dilution. Primary antibodies were labeled with goat antimouse IgG at a
1:10,000 dilution or with goat antirabbit IgG at a 1:4500 dilution
conjugated with horseradish peroxidase (Dako, Hamburg, Germany) for
1 h. Immunoreactive bands were visualized by incubation of the
membrane with Super Signal West Pico reagent from Pierce.
Quanti®cation of the Bax/Bcl-2 ratio Quantitative analysis of the
Bax/Bcl-2 protein expression was performed using a scanning
densitometer and Multianalyst Software Version 1.0.2 (Biorad, Munich,
Germany) as described previously (Prokop et al, 2000). Standardization of
protein loading was achieved as follows: (i) protein measurements of all
samples were performed using the bicinchoninic acid assay and equal
amounts of protein (35 mg per lane) were loaded on the gel; (ii) transfer
ef®ciency of the Western blots was routinely checked by staining the
membranes with 0.5% Ponceau Red in 1% acetic acid; (iii) for
chemiluminescent detection, ®lms were exposed exactly the same length
of time, which was optimized for each antibody used in this study; and
(iv) detection of Bax and Bcl-2 was performed separately on the same
membrane. Thus, this procedure is valid to determine the protein ratios
in the same sample (on the same lane of the gel). Values of protein
expression are given in arbitrary units. Linearity of protein detection was
checked for Bax and Bcl-2 using standard cell extracts from BJAB cells
(Prokop et al, 2000).
Cytotoxicity assays Cytotoxicity was determined with the
cytotoxicity detection kit (LDH) from Roche Diagnostics (Mannheim,
Germany) as described previously (Bektas et al, 1998). After treatment of
cells for different times, cell culture supernatants were removed and
clari®ed by centrifugation at 300 3 g for 5 min. 100 ml of the
supernatants were transferred to 96-well microtiter plates and lactate
dehydrogenase (LDH) activity was determined by addition of substrate
solution; formation of the formazan salt was measured at 492 nm.
Extinction values of control cells were set as 100% and the rate of LDH
release from treated cells was calculated as a percentage of control.
Cell death detection Con¯uent cells in 24-well plates were treated
with the respective agents or control vehicle in DMEM. After distinct
times of incubation, cell death was measured in a photometric enzyme
immunoassay for the qualitative and quantitative in vitro determination of
cytoplasmic histone-associated DNA fragments (mononucleosomes and
oligonucleosomes) with the commercially available kit ``Cell death
detection ELISAPLUS'' from Roche Diagnostics, as described previously
(Wieder et al, 1998). Brie¯y, cells were centrifuged at 300 3 g, washed
with PBS, pH 7.2, and lyzed with lysis buffer. Then, a clear cytosolic
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supernatant was prepared by centrifugation (300 3 g, 5 min). 20 ml of
the respective supernatants were added to a streptavidin-coated 96-well
microtiter plate. After addition of 80 ml of a solution containing
antihistone-biotin and anti-DNA-peroxidase conjugates in incubation
buffer the samples were incubated under moderate shaking for 2 h at
room temperature. Subsequently, the wells were washed three times
with incubation buffer, 100 ml substrate solution was added, and the
samples were incubated for 10 min at room temperature in the dark.
Then, the extinction was measured at 405 nm. The values of cells that
were treated with control medium were set at 100% and the apoptosis
rates of treated cells were calculated as a percentage of control.
Mutational analysis of p53 DNA from 11 melanoma cell populations
was extracted using the QIAamp Tissue Kit (Qiagen, Hilden, Germany).
p53 mutations in the DNA binding region (exons 5±8) were investigated
by single stranded conformational polymorphism (SSCP) polymerase
chain reaction (PCR) analysis. Oligonucleotide primer sequences, PCR
conditions, and the SSCP protocol for p53 mutational analysis were as
described elsewhere, with one modi®cation: PAGE was performed at
22°C (Sturm et al, 1999).
PCR products that showed an aberrant SSCP pattern were sequenced
with the ABI Prism Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (PE Applied Biosystems, Weiterstadt, Germany) according
to the manufacturer's recommendation with the same primers used for
PCR ampli®cation. Sequencing was performed with an ABI Prism 310
sequencer. Sequence analysis was performed with the software
Sequencher 3.0 (Gene Codes Corporation, Ann Arbor, MI).
Preparation of cytosolic extracts and mitochondria Mitochondrial
and cytosolic extracts were prepared according to a method described
previously (Liu et al, 1996). After incubation with betulinic acid, cells
were harvested in PBS, equilibrated in hypotonic buffer (20 mM
HEPES, pH 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM ethylenediamine
tetraacetic acid), and centrifuged at 300 3 g for 5 min. The resulting
pellets were then dissolved in hypotonic buffer containing phenyl-
methylsulfonyl ¯uoride (®nal concentration 0.1 mM) and incubated on
ice for 15 min. Cells were homogenized by passing the cells through a
syringe (G 20) approximately 20 times. The membranes were isolated by
2-fold centrifugation at 10,000 3 g at 4°C for 10 min and the super-
natant of the second centrifugation was used as cytosolic extract. The
resulting mitochondrial pellets were solubilized in lysis buffer (1% Triton
X-100, 50 mM Tris, pH 7.4, 150 mM NaCl containing 1 mM
leupeptin, 1 mM pepstatin, and 100 mM phenylmethylsulfonyl ¯uoride)
and together with the clear supernatants stored at ±80°C. Western blot
analyses with cytosolic and mitochondrial extracts were performed as
described before and conducted with mouse monoclonal anti-
cytochrome c antibodies (7H8.2C12, Pharmingen) at a 1:1000 dilution.
The second horseradish-peroxidase-coupled antimouse antibody (Dako)
was used at a 1:10,000 dilution.
RESULTS
Bax and Bcl-2 protein expression in melanoma cell
populations A panel of 11 melanoma cell populations was
screened for expression of two counteracting proteins of the Bcl-2
family, Bax and Bcl-2. For this, proteins extracted from distinct
melanoma cell populations were analyzed by Western blot.
Antibodies against both proteins were used subsequently on the
same membrane. The protein levels of the two cytoplasmic proteins
in the different cell populations showed great variations for both
proteins (Fig 1). We observed a difference in protein expression
between CD95-sensitive and CD95-resistant melanoma cells,
however. Whereas CD95-sensitive cell lines revealed a higher
expression of Bax in relation to Bcl-2, CD95-resistant cells showed
low Bax/Bcl-2 ratios (Fig 1).
Quanti®cation of the Bax/Bcl-2 ratio Quantitative analysis of
the Bax and Bcl-2 protein expression was performed using a
scanning densitometer. The quantitative Bax and Bcl-2 protein
expression levels and the Bax/Bcl-2 ratios are listed in Table I.
Interestingly, we found that a Bax/Bcl-2 ratio < 1.00 was
characteristic for resistant cells and a Bax/Bcl-2 ratio > 1.00 for
sensitive melanoma cells. Statistical analysis revealed that this
®nding was signi®cant (p < 0.0022, Fisher's exact test; p < 0.0009,
chi-squared test). Thus, our data clearly support the hypothesis that
the Bax/Bcl-2 ratio forms a rheostat that determines the sensitivity
to CD95-induced apoptosis in human melanoma cells.
Overexpression of Bcl-2 prevents CD95- and ceramide-
induced apoptosis Bcl-2 has been shown to maintain cell
Figure 1. Determination of Bax and Bcl-2 protein expression in
human melanoma cells. Protein extracts from 11 melanoma cell
populations were prepared and equal amounts of protein (35 mg per lane)
were separated by SDS-PAGE. After transfer on nitrocellulose
membrane, immunodetection was carried out using anti-Bax antibodies
and anti-Bcl-2 antibodies. Arrows at the right margin indicate the
migration positions of Bax and Bcl-2 proteins.
Table I. Correlation of CD95 sensitivity with the intraexperimental quanti®cation of the Bax/Bcl-2 ratio
Cell populations
Susceptibility
to CH-11a
Susceptibility
to C2-ceramide
Bax O.D.
[arbitrary units]b
Bcl-2 O.D.
[arbitrary units]b Bax/Bcl-2 ratioc
MelHo ++ ++ 0.067 0.045 1.49
A375 +++ +++ 0.048 0.025 1.93
M186 + + 0.693 0.186 3.73
BRO ++ ++ 0.208 0.089 2.34
SkMel13 + + 0.518 0.062 8.36
M221 ± ± 0.047 0.058 0.82
SkMel23 (p53 mut.)d ± ± 0.071 0.396 0.18
MEWO (p53 mut.)d ± ± 0.030 0.201 0.15
Mel2A ± ± 0.034 0.096 0.36
SkMel28 ± ± 0.040 0.098 0.41
JPC298 ± ± 0.111 0.285 0.39
a+, low sensitivity (apoptotic cells 200% of control); ++, mean sensitivity (apoptotic cells 200%±300% of control); +++, high sensitivity (apoptotic cells 300%±600% of
control) as measured by cell death detection ELISA
bValues of Bax and Bcl-2 expression in different melanoma cell populations were quanti®ed by scanning densitometry of the Western blot shown in Fig 1 using the
Multianalyst Software Version 1.0.2 (Biorad) and are given in arbitrary units.
cA Bax/Bcl-2 ratio < 1.00 characterizes CD95-resistant cells and a Bax/Bcl-2 ratio > 1.00 CD95-sensitive melanoma cells.
dp53 mut., p53 mutated.
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viability by blocking cytochrome c release and preventing loss of
mitochondrial membrane potential (Yang et al, 1997). In order to
further elucidate the role of the Bax/Bcl-2 rheostat in our
experimental system, we overexpressed the bcl-2 gene in two
melanoma cell lines, A375 and MelHo, which were shown to be
highly sensitive to CD95- and ceramide-induced apoptosis. The
overexpression shifted the Bax/Bcl-2 ratio from 1.93 and 1.49 in
A375 and MelHo, respectively, to approximately 0.04 and 0.03 in
the corresponding transfected cell lines as determined using the
mouse and human reactive anti-bcl-2 antibodies C-2. We could
show that Bcl-2 overexpression in A375 and MelHo cell lines
rendered these cells completely resistant to treatment with 1 mg per
ml agonistic anti-CD95 monoclonal antibody CH-11 (Fig 2A).
Furthermore, the sensitivity to ceramide-induced apoptosis was
tested. For this purpose, bcl-2 transfected A375 and MelHo cells
were treated with C2-ceramide, a cell-permeable short acyl chain
ceramide. These experiments revealed that overexpression of the
bcl-2 gene also prevented apoptosis induced by 30 mM C2-ceramide
after 6 h of incubation (Fig 2B). These ®ndings suggest that
mitochondrial alterations are the key events, determining the fate of
melanoma cells upon treatment with different apoptotic stimuli,
such as CD95L and C2-ceramide.
Low Bax expression is not exclusively caused by p53
mutations Induction of Bax expression has been attributed to
the wild-type form of the tumor suppressor p53, which binds to
typical recognition elements located in the bax gene promoter and
directly transactivates this proapoptotic gene. Therefore, we
evaluated whether the differential expression of Bax in melanoma
cells is in¯uenced by the p53 mutational status. More than 90% of
p53 mutations occur in the DNA-binding site of p53, which is
encoded by exons 5±8. p53 mutations, as assessed by mutational
analysis using SSCP-PCR, were found in exon 7 of the p53 gene in
two melanoma cell lines, SkMel 23 and MEWO (Fig 3).
Sequencing revealed a codon 248 mutation in SkMel23 (CGG
® TGG, arginine ® tryptophan) and a codon 258 mutation in
MEWO (GAA ® AAA, glutamic acid ® lysine). Both cell lines
showed a Bax/Bcl-2 ratio < 1 and were resistant to CD95-induced
apoptosis, thereby providing evidence that low Bax levels in these
cells might be a direct consequence of the loss of functional p53.
p53 mutation, however, cannot serve as an explanation for low Bax
expression and resistance to CD95-induced apoptosis in other cell
populations, e.g., M221, Mel2A, SkMel28, and JPC 298.
Furthermore, there was no statistically signi®cant correlation
between low Bax expression and p53 mutational status (p < 0.5,
Fisher's exact test; p < 0.2, chi-squared test).
Betulinic acid bypasses the resistance to CD95-induced
apoptosis In the previous experiments we could show that the
mitochondrion is a central player in CD95- and ceramide-induced
apoptosis in human melanoma cells. We therefore reasoned that the
apoptosis de®ciency of resistant melanoma cells can be
circumvented by drugs directly targeting mitochondria and
causing cytochrome c release. For this purpose, we tested
betulinic acid, a selective cytotoxic agent for melanoma and
other cells of neuroectodermal origin (Fulda et al, 1999). In a ®rst
set of experiments, cytotoxicity of betulinic acid on melanoma cells
was determined by measurement of the release of LDH into the cell
culture supernatants. In these experiments, 10 mg per ml betulinic
acid was shown to be the most effective concentration triggering
apoptosis in melanoma cells without affecting plasma membrane
integrity (data not shown). Additionally, CD95-sensitive as well as
CD95-resistant melanoma cells that had been treated with betulinic
acid exhibited typical morphologic features of apoptotic cells as
observed under the light microscope (data not shown). Apoptotic
cell death was con®rmed by measurement of DNA fragmentation
in betulinic-acid-treated cells. As shown in Fig 4, betulinic acid
treatment of A375, M186 (CD95-sensitive cells) and M221, Mel2A
Figure 2. The involvement of Bcl-2 in CD95- and ceramide-
induced apoptosis. Nontransfected (A375 and MelHo) and bcl-2
transfected (A375/Bcl-2 and MelHo/Bcl-2) melanoma cell lines were
treated either with 1 mg per ml agonistic anti-CD95 monoclonal
antibody CH-11 for 12 h (A) or with 30 mM C2-ceramide for 6 h (B).
DNA fragmentation was measured photometrically using an enzyme-
linked immunoassay for determination of cytoplasmic histone-associated
DNA fragments. Gray columns represent CH-11- or C2-ceramide-treated
cells and black columns untreated control cells. DNA fragmentation of
control cells was set as 100% and DNA fragmentation of treated cells was
calculated as a percentage of control. Values represent the mean of three
experiments 6 SD (*p < 0.0001; **p < 0.001).
Figure 3. Mutational analysis of p53 in melanoma cell lines. The
mutational analysis of p53 in melanoma cell lines was assessed by SSCP-
PCR. Two of the CD95-resistant cell lines, SkMel23 and MEWO,
revealed a mutation of p53 in exon 7. Migration positions of single-
stranded DNA (+), double-stranded DNA (+ + +), and aberrant bands
(arrows) are indicated (WT, wild-type p53; 59, SkMel23; 56, MEWO).
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(CD95-resistant cells) clearly induced DNA fragmentation.
Additionally, apoptosis induction was also observed in SkMel23
and MEWO, two cell lines with mutated p53 (Fig 5), indicating a
p53-independent mechanism. In some cases DNA fragmentation in
betulinic-acid-treated cells reached 400% compared with control
cells, indicating that this compound represents an effective inducer
of apoptosis, even in cells with a blockade in the upstream
apoptotic pathway.
Bcl-2 overexpression partially inhibits betulinic-acid-
induced apoptosis in melanoma cells To elucidate the role
of Bcl-2 in betulinic-acid-induced cell death, we measured DNA
fragmentation in Bcl-2 transfected A375 and MelHo cells. We
could show that Bcl-2 overexpression in A375 and MelHo cell
lines reduced the apoptosis triggered by betulinic acid in A375/
Bcl-2 by 79% and in MelHo/Bcl-2 by 74% (Fig 6). In contrast to
CD95- and ceramide-induced apoptosis, however, Bcl-2
overexpression did not completely block the effect of betulinic
acid.
Betulinic-acid-triggered cytochrome c release occurs in
CD95-sensitive cells as well as CD95-resistant melanoma
cells To gain insight into the molecular effector pathway of
betulinic acid, we investigated the effect of betulinic acid on
cytochrome c release from mitochondria. Cytosolic extracts of
melanoma cells were prepared and cytochrome c release after
stimulation was determined by Western blot analysis.
Mitochondrial extracts of the different cell lines were included as
positive controls. As shown in Fig 7, stimulation of the CD95-
sensitive melanoma cells A375 and M186 as well as the CD95-
resistant cell lines Mel2A and M221 with betulinic acid provoked
the translocation of cytochrome c into the cytosol. Thus, these
results exclude a general defect in cytochrome c release at the level
of mitochondrial transition pore formation in CD95-resistant
melanoma cells but rather point to the key role of the upstream
Bax/Bcl-2 rheostat.
Betulinic acid induces activation of caspase-9 in sensitive
and resistant cell lines In order to determine the status of
caspase-9 level and activation in our experimental set-up, we
performed Western blot analyses using anticaspase-9 antibodies. As
shown in Fig 8, both sensitive and resistant melanoma cell
populations showed the active cleavage forms of caspase-9 upon
treatment with betulinic acid. This further con®rmed the role of
mitochondrial factors in betulinic-acid-treated melanoma cells.
Interestingly, Jurkat cells did not show activation of caspase-9
(Fig 8), thereby verifying the speci®city of betulinic acid for cells of
neuroectodermal origin.
DISCUSSION
Melanoma cell populations exhibit differential sensitivity to CD95-
induced apoptosis. The evaluation of the mechanisms underlying
the apoptosis de®ciency of CD95-resistant melanoma cells revealed
a failure to translocate cytochrome c into the cytosol and pointed to
the central role of mitochondria in this pathway (Raisova et al,
2000). The analysis of proteins, regulating mitochondrial functions,
showed a correlation between the ratio of two members of the
Bcl-2 protein family, Bax and Bcl-2, and sensitivity to CD95-
mediated apoptosis. In our experimental system, a Bax/Bcl-2 ratio
< 1.00 was characteristic for CD95-resistant cells whereas a Bax/
Bcl-2 ratio > 1.00 was characteristic for sensitive melanoma cells.
The Bax/Bcl-2 ratio was also in correlation with the sensitivity of
melanoma cells to another proapoptotic molecule, C2-ceramide.
Figure 4. Betulinic acid bypasses resistance to CD95-induced
apoptosis. CD95-sensitive (A375 and M186) and CD95-resistant
(Mel2A and M221) melanoma cell lines were treated with 10 mg per ml
betulinic acid for 24 h. DNA fragmentation was measured photo-
metrically using an enzyme-linked immunoassay for determination of
cytoplasmic histone-associated DNA fragments. Gray columns represent
betulinic-acid-treated cells and black columns untreated control cells.
Control cells were set as 100% and treated cells were calculated as a
percentage of control. Values represent the mean of three experiments
6 SD (*p < 0.0001).
Figure 5. Betulinic acid induces apoptosis in p53 mutated cell
lines SkMel23 and MEWO. Melanoma cell lines were treated with
10 mg per ml betulinic acid for 24 h. DNA fragmentation was measured
photometrically using an enzyme-linked immunoassay for determination
of cytoplasmic histone-associated DNA fragments. Gray columns represent
betulinic-acid-treated cells and black columns untreated control cells.
Control cells were set as 100% and treated cells were calculated as a
percentage of control. Values represent the mean of three experiments 6
SD (*p < 0.0001).
Figure 6. The involvement of Bcl-2 in betulinic-acid-induced
apoptosis. Nontransfected (A375 and MelHo) and bcl-2 transfected
(A375/Bcl-2 and MelHo/Bcl-2) melanoma cell lines were treated with
10 mg per ml betulinic acid for 24 h. DNA fragmentation was measured
photometrically using an enzyme-linked immunoassay for determination
of cytoplasmic histone-associated DNA fragments. Gray columns represent
betulinic-acid-treated cells and black columns untreated control cells. DNA
fragmentation of control cells was set as 100% and DNA fragmentation
of treated cells was calculated as a percentage of control. Values represent
the mean of three experiments 6 SD (*p < 0.0001; **p < 0.02).
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Ectopic Bcl-2 overexpression in sensitive cell lines prevented
apoptosis triggered by both apoptotic stimuli, thereby supporting
the role of the Bax/Bcl-2 rheostat as a key checkpoint that
determines the susceptibility to CD95- and ceramide-induced
apoptosis in melanoma cells. The broad resistance to cell death,
occurring upon disturbed balance in the Bax/Bcl-2 ratio, has
potential relevance for cancer cell behavior, tumor cell invasion,
cell adhesion, or metastatic potential (Reed, 1999). For example,
overexpression of Bcl-2 in the murine melanoma cell line B16
strongly enhanced melanoma pulmonary metastasis in allogenic
BALB/c nude mice (Takaoka et al, 1997). This increased metastatic
potential supports the idea of a correlation of melanoma metastasis
promotion and the ability of Bcl-2 to protect tumor cells from
apoptosis. Disturbances in the Bax/Bcl-2 balance, tilting the scales
towards survival, can enhance the resistance of tumor cells to the
cytotoxic effects of essential chemotherapeutic drugs. In this
context, cytotoxic anticancer drugs have been shown to involve
apoptotic pathways entering at different sites: either by a CD95L/
CD95-driven ampli®er system (doxorubicin, cisplatin) (Fulda et al,
1998a), ceramide generation (daunorubicin, adriamycin) (Jaffrezou
et al, 1996; Lucci et al, 1999), or direct activation of upstream
caspases (mitomycin C, etoposide) (Wesselborg et al, 1999). Thus,
most of the interventions by cancer therapy enter the apoptotic
pathway upstream of the mitochondrial checkpoint, where they
converge into the common effector phase of apoptosis.
Modi®cation of the Bax/Bcl-2 protein level as a novel modality
has been investigated by bcl-2 antisense oligonucleotides therapy in
melanoma (Jansen et al, 1998). Experimental settings using this
technique revealed an inverse correlation between chemosensitivity
and Bcl-2 levels. This ®nding indicates that the endogenous Bcl-2
protein levels contribute to melanoma drug resistance. The Bax/
Bcl-2 ratio can be altered by the tumor suppressor p53. Wild-type
p53 is known to upregulate the expression of Bax, thereby creating
a link between Bax expression and the mutational status of p53
(Miyashita et al, 1994). The mutational analysis of p53 in melanoma
cell lines revealed mutations in the coding region of the p53 gene in
two cell lines with a Bax/Bcl-2 ratio < 1. Loss of functional p53
might therefore be responsible for lower Bax expression in these
two cell populations but cannot serve as a suf®cient explanation for
low Bax/Bcl-2 ratios in the remaining resistant cell lines.
According to our results, it should be possible to circumvent the
apoptosis de®ciency of melanoma cells by drugs directly in¯uencing
the mitochondrial function (as shown in Fig 9). For this purpose,
Figure 7. Cytochrome c is released upon stimulation with
betulinic acid in CD95-sensitive (A375 and M186) as well as in
CD95-resistant (Mel2A and M221) melanoma cells. Cells were
harvested after 12 h stimulation with 10 mg per ml betulinic acid. For
the detection of cytochrome c release, cytosolic and mitochondrial
extracts were prepared as described in Materials and Methods. Western
blot was performed with antihuman cytochrome c antibodies (mitoch.,
mitochondrial extracts; Bet. Acid, betulinic acid).
Figure 8. Activation of caspase-9 after treatment with betulinic
acid in sensitive and resistant melanoma cell lines A375, M186,
and Mel2A. Mel2A, M186, and A375 cells were harvested after 14 h
treatment with 10 mg per ml betulinic acid (+) or control medium (±).
Additionally the CD95-sensitive lymphoma cell line Jurkat was treated in
the same way and used as control. For the detection of caspase-9
activation, Western blot analysis was performed with antihuman caspase-
9 antibodies (Bet. Acid, betulinic acid; *procaspase-9, **36 kDa
processed form, ***25 kDa processed form).
Figure 9. The apoptotic rheostat of the
melanoma cell. Imbalances in the ratios of
antiapoptotic and proapoptotic Bcl-2 family
members that tilt the scales toward survival can
render melanoma cells more resistant to different
apoptotic stimuli. In contrast, a new class of
cytotoxic drugs, exempli®ed by betulinic acid, may
directly trigger mitochondrial activation. On
the other hand, p53 is known to upregulate the
expression of the bax gene, thereby altering the
Bax/Bcl-2 ratio. During apoptosis, cytochrome c is
released from mitochondria and binds to cytosolic
Apaf-1 (apoptotic protease activating factor 1) and
procaspase-9. This in turn results in activation of
caspase-9 and processing of caspase-3.
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we tested betulinic acid, a cytotoxic agent selective for melanoma,
directly targeting mitochondria (Fulda et al, 1999; Selzer et al,
2000). Betulinic acid has been shown to act independently of the
CD95 pathway and p53 activation by straight perturbance of
mitochondrial functions (Fulda et al, 1997). A controversy was
raised, however, by a report that betulinic acid exerts its inhibitory
effect by increasing p53 (Rieber et al, 1998). In our system,
betulinic-acid-induced apoptosis was in the same range in the p53
mutated cells as in the p53 wild-type cells and thus should be
considered independent of the p53 system. Furthermore, betulinic
acid was able to bypass the mitochondrial blockade in CD95-
resistant melanoma cells and induced cytochrome c release and
DNA fragmentation in both CD95-resistant and sensitive cells,
independent of the Bax/Bcl-2 ratio.
Several experimental and clinical studies of other tumors
provided support for higher expression levels of antiapoptotic
Bcl-2 proteins as a negative prognostic marker. Furthermore, an
apparent upregulation of Bcl-2 in patients with various tumors has
been observed at the time of relapse of the disease. On the other
hand, high Bax expression could be associated with a better
response to chemotherapy in ovarian cancer and decreased Bax
levels have been found in correlation with shorter survival in
patients with breast cancer and colorectal cancer (Bargou et al,
1996; Sturm et al, 1999). Disbalances in the Bax/Bcl-2 ratio have
been shown to be a determining prognostic factor for breast cancer
and a study with 111 patients provided evidence that decrease of
Bax was associated with relapse of childhood acute lymphoblastic
leukemia (Prokop et al, 2000). In addition to transcriptional
regulation of Bcl-2 family members, Bcl-2 family molecules are
also subject to post-transcriptional regulation. These mechanisms
include modi®cations of proapoptotic proteins, such as Bad, or
antiapoptotic proteins, such as Bcl-2 and Bcl-xL (Gajewski and
Thompson, 1996; Wang et al, 1999). Phosphorylation by Akt/
protein kinase B and other kinases inactivates these proteins and
may conceivably be linked to differential responses to cytostatic
therapy (Downward, 1998).
In conclusion, mitochondria with the main orchestrators Bax
and Bcl-2 play a central role in the regulation of CD95- and
ceramide-induced apoptosis in human melanoma cells. Our
®ndings will therefore help in understanding the mechanisms by
which apoptosis pathways are regulated in melanoma and provide
useful links for developing strategies to improve the ef®cacy of
anticancer therapy.
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